Although we do observe an inverse relationship between NQO1 and STAT1 levels in these breast cancer PDXs (Supplementary Figure 9a, b), the NQO1/STAT1 ratio is not sufficient to predict relative sensitivity to combined β-lapachone/phenformin treatment (Supplementary Figure 9c). This evidence concerns the gene NQO1 and breast carcinoma.